The Role of Everolimus in Renal Cell Carcinoma

Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal ce...

Full description

Saved in:
Bibliographic Details
Published in:Journal of kidney cancer and VHL 2015-01, Vol.2 (4), p.187-194
Main Authors: Meskawi, Malek, Valdivieso, Roger, Dell'Oglio, Paolo, Trudeau, Vincent, Larcher, Alessandro, Karakiewicz, Pierre I
Format: Article
Language:English
Subjects:
Everolimus
Inhibitor drugs
Kidney cancer
Monoclonal antibodies
renal cell carcinoma
Review
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal cell carcinoma (RCC). In this study, everolimus was used after failure of one or several previous lines of therapy, and it demonstrated a 3-month survival benefit relative to placebo. Currently, based on the level 1 evidence, everolimus represents the molecule of choice for third-line therapy after failure of previous two tyrosine kinase inhibitors (TKIs). However, second-line use after failure of one TKI is challenged by two new molecules (nivolumab and cabozantinib), which proved to have better efficacy with similar toxicity profile. In non-clear cell metastatic RCC, the current evidence recommends everolimus as a second-line therapy after failure of previous first-line sunitinib.
ISSN:2203-5826
2203-5826
DOI:10.15586/jkcvhl.2015.43